Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The chromatin accessibility signature of human immune aging stems from CD8+ T cells.

Ucar D, Márquez EJ, Chung CH, Marches R, Rossi RJ, Uyar A, Wu TC, George J, Stitzel ML, Palucka AK, Kuchel GA, Banchereau J.

J Exp Med. 2017 Oct 2;214(10):3123-3144. doi: 10.1084/jem.20170416. Epub 2017 Sep 13.

2.

The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells.

Marches R, Mikoryak C, Wang RH, Pantano P, Draper RK, Vitetta ES.

Nanotechnology. 2011 Mar 4;22(9):095101. doi: 10.1088/0957-4484/22/9/095101. Epub 2011 Jan 24.

PMID:
21258147
3.

Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies.

Marches R, Chakravarty P, Musselman IH, Bajaj P, Azad RN, Pantano P, Draper RK, Vitetta ES.

Int J Cancer. 2009 Dec 15;125(12):2970-7. doi: 10.1002/ijc.24659.

4.

Tumor cell dormancy: implications for the biology and treatment of breast cancer.

Fehm T, Mueller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, Becker S.

APMIS. 2008 Jul-Aug;116(7-8):742-53. doi: 10.1111/j.1600-0463.2008.01047.x. Review.

PMID:
18834416
5.

Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes.

Chakravarty P, Marches R, Zimmerman NS, Swafford AD, Bajaj P, Musselman IH, Pantano P, Draper RK, Vitetta ES.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8697-702. doi: 10.1073/pnas.0803557105. Epub 2008 Jun 16.

6.

Cancer dormancy: from mice to man.

Marches R, Scheuermann R, Uhr J.

Cell Cycle. 2006 Aug;5(16):1772-8. Epub 2006 Aug 15. Review.

PMID:
16929181
7.

Mathematical models of the fate of lymphoma B cells after antigen receptor ligation with specific antibodies.

Alarcón T, Marches R, Page KM.

J Theor Biol. 2006 May 7;240(1):54-71. Epub 2005 Oct 7.

PMID:
16214175
10.

Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES.

Clin Cancer Res. 2002 Jun;8(6):1720-30.

11.

Dormancy in a model of murine B cell lymphoma.

Uhr JW, Marches R.

Semin Cancer Biol. 2001 Aug;11(4):277-83. Review.

PMID:
11513563
12.

A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas.

Marches R, Vitetta ES, Uhr JW.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3434-9. Epub 2001 Feb 27.

13.
14.

Antigen receptor signaling induces differential tyrosine kinase activation and population stability in B-cell lymphoma.

Hsueh RC, Hammill AK, Marches R, Uhr JW, Scheuermann RH.

Curr Top Microbiol Immunol. 1999;246:299-304; discussion 305. Review. No abstract available.

PMID:
10396069
15.
16.

Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established.

Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW.

Blood. 1997 Jun 15;89(12):4425-36.

PMID:
9192767
17.

Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction.

Racila E, Hsueh R, Marches R, Tucker TF, Krammer PH, Scheuermann RH, Uhr JW.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2165-8.

18.

Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).

Mota G, Marches R, Cialacu V, Roman V, Kozma E, Mărgineanu M, Dima S, Moraru II.

Arch Immunol Ther Exp (Warsz). 1996;44(2-3):131-6.

PMID:
8915518
19.

Role of antibody signaling in inducing tumor dormancy.

Uhr JW, Marches R, Racila E, Tucker TF, Hsueh R, Street NE, Vitetta ES, Scheuermann RH.

Adv Exp Med Biol. 1996;406:69-74. Review. No abstract available.

PMID:
8910672
20.

Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells.

Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hsueh R, Vitetta ES, Scheuermann RH, Uhr JW.

Ther Immunol. 1995 Jun;2(3):125-36.

PMID:
8885131
21.

Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.

Racila E, Scheuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, Marches R, Street NE, Vitetta ES, Uhr JW.

J Exp Med. 1995 Apr 1;181(4):1539-50.

22.

Interleukin 2 enhances the efficiency of immunotoxins in the treatment of mice with ascitic tumors.

Margineanu M, Marches R, Dima S, Cialacu V, Kozma E, Savi G, Stavri H, Badea E, Bancu A, Mota G.

Neoplasma. 1991;38(6):633-8.

PMID:
1766487
23.

Treatment of murine EL4 leukemia in ascitic form with anti-Thy 1.2 specific immunotoxins.

Marches R, Mota G, Margineanu M, Stavri H, Savi G, Nicolae M, Bancu A, Moraru I.

Neoplasma. 1990;37(5):573-8.

PMID:
2234217
24.

Experimental model for testing the efficiency of immunotoxins administered in vivo: evaluation of two ricin A-chain--multivalent antibody immunotoxins.

Moţa G, Mărgineanu M, Marcheş R, Nicolae M, Bancu A, Moraru I.

Immunol Lett. 1989 Mar;20(4):283-91.

PMID:
2785502
25.

Interaction between human IgD and ricinus agglutinin.

Marches R, Ghetie V.

Scand J Immunol. 1986 Jul;24(1):45-8.

PMID:
3726458

Supplemental Content

Loading ...
Support Center